Evaluation of RenalGuard® System to Reduce the Incidence of Contrast Induced Nephropathy in At-Risk Patients
NCT01456013
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
326
Enrollment
INDUSTRY
Sponsor class
Conditions
Contrast Induced Nephropathy
Interventions
DEVICE:
RenalGuard Therapy
DRUG:
Standard Therapy
Sponsor
CardioRenal Systems, Inc.